Hims & Hers Health, Inc. (NYSE:HIMS) Position Reduced by AQR Capital Management LLC

AQR Capital Management LLC lowered its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 43.5% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 47,887 shares of the company’s stock after selling 36,899 shares during the period. AQR Capital Management LLC’s holdings in Hims & Hers Health were worth $967,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 14,173,285 shares of the company’s stock valued at $126,142,000 after acquiring an additional 46,541 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $155,000. Los Angeles Capital Management LLC lifted its position in shares of Hims & Hers Health by 58.5% in the 1st quarter. Los Angeles Capital Management LLC now owns 28,206 shares of the company’s stock worth $436,000 after buying an additional 10,405 shares during the last quarter. Fragasso Group Inc. acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at about $243,000. Finally, Counterpoint Mutual Funds LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter valued at about $285,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Bank of America cut their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a report on Friday, September 13th. Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target on the stock. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Jefferies Financial Group increased their target price on Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, June 27th. Finally, TD Cowen boosted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 11th. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $19.86.

Hims & Hers Health Trading Up 4.7 %

Shares of NYSE:HIMS opened at $18.69 on Friday. The company has a 50 day moving average of $16.41 and a 200-day moving average of $17.37. The firm has a market cap of $4.01 billion, a P/E ratio of 233.65 and a beta of 1.06. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The firm’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.03) earnings per share. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Activity

In related news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,077,172. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Michael Chi sold 2,054 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the completion of the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at $4,077,172. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,334 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the transaction, the insider now owns 164,475 shares in the company, valued at approximately $2,845,417.50. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 564,305 shares of company stock worth $9,124,922 over the last 90 days. 17.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.